Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …

High-dimensional approaches have revealed heterogeneity amongst dendritic cells (DCs),
including a population of transitional DCs (tDCs) in mice and humans. However, the origin …

Objective Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic
steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data …

Background Metastatic colonization is one of the critical steps in tumor metastasis. A pre-
metastatic niche is required for metastatic colonization and is determined by tumor-stroma …

SHP2 mediates the activities of multiple receptor tyrosine kinase signaling and its function in
endothelial processes has been explored extensively. However, genetic studies on the role …

Developmental origins of dendritic cells (DCs) including conventional DCs (cDCs,
comprising cDC1 and cDC2 subsets) and plasmacytoid DCs (pDCs) remain unclear. We …

Although RAS was formerly considered undruggable, various agents that inhibit RAS or
specific RAS oncoproteins have now been developed. Indeed, the importance of directly …

Over the past decade, RAS oncogenic proteins have transitioned from being deemed
undruggable to having two clinically approved drugs, with several more in advanced stages …

Summary KRAS G12C inhibitors (adagrasib and sotorasib) have shown clinical promise in
targeting KRAS G12C-mutated lung cancers; however, most patients eventually develop …